All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or Myeloma crowd.
The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
During the 8th World Congress on Controversies in Multiple Myeloma (COMy), the Multiple Myeloma Hub was pleased to speak to Hermann Einsele, Julius-Maximilians-Universität Würzburg, Würzburg, DE. We asked, How do you manage bridging therapies prior to CAR T cells in multiple myeloma?
How to manage bridging therapies prior to CAR T cells in multiple myeloma?
Einsele begins by explaining why bridging therapy is important in patients with multiple myeloma with a high tumor load. This is followed by a discussion on what should be considered when choosing a bridging therapy regimen, such as the incidence of cytopenias and infection risk.
Subscribe to get the best content related to multiple myeloma delivered to your inbox